Can a One-Two punch wake up and destroy hidden HIV?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria A participant will be deemed eligible for enrollment only if all of the following criteria are met: 1. Diagnosis of HIV infection, with a current history of highly active antiretroviral therapy (HAART) for a minimum duration of two years. 2. Age between 18 and 65 years, inclusive. 3. Plasma HIV RNA level \< 50 copies/mL (virologic suppression). 4. CD4⁺ T cell count \> 200 cells/μL. 5. Adequate hematologic function defined as: * Hemoglobin ≥ 90 g/L; * Platelet count ≥ 75 × 10⁹/L; * Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L; * White blood cell count ≥ 2 × 10⁹/L. 6. Adequate hepatic and renal function defined as: * Serum creatinine ≤ 1.5 × upper limit of normal (ULN); * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN; * Total bilirubin ≤ 2 × ULN; * Prothrombin time (PT) prolongation \< 3 seconds. 7. Hemodynamically stable with a left ventricular ejection fraction (LVEF) ≥ 45%. 8. Negative serum or urine pregnancy test for females of childbearing potential. 9. Willingness of the participant to: * Practice effective contraception during the study period and for one year following completion of the trial; * Voluntarily provide written informed consent and comply with scheduled follow up visits and study procedures. Exclusion Criteria Participants meeting any of the following criteria will be excluded from study participation: 1. Presence of severe cardiovascular, respiratory, or hematologic disease; active infectious disease (other than controlled HIV infection); or active malignancy. 2. Positive serology for hepatitis B surface antigen (HBsAg) or detectable hepatitis C virus RNA (HCV RNA). 3. Diagnosis of chronic kidney disease (CKD). 4. History or presence of acute or chronic pancreatitis. 5. Active severe peptic ulcer disease. 6. Current severe neurologic or psychiatric disorder. 7. History of alcohol abuse or illicit substance use disorder. 8. Known allergic diathesis or hypersensitivity to any component of the investigational agents. 9. Female participants who are pregnant, lactating, or of childbearing potential and unwilling to adhere to required contraceptive measures. 10. Concurrent use of immunosuppressive agents. 11. Any other condition that, in the opinion of the investigator, renders the participant unsuitable for study participation.